摘要
Verinurad (RDEA3170) is a selective URAT1 inhibitor under investigation for the treatment of gout and hyperuricemia. In an effort to further improve the pharmacodynamics/pharmacokinetics of verinurad and to increase the structural diversity, we designed novel verinurad analogs by introducing a linker (e.g. aminomethyl, amino or oxygen) between the naphthalene and the pyridine ring to increase the flexibility. These compounds were synthesized and tested for their in vitro URAT1-inhibitory activity. Most compounds exhibited potent inhibitory activities against URAT1 with IC50 values ranging from 0.24 mM to 16.35 mM. Among them, compound KPH2f exhibited the highest URAT1-inhibitory activity with IC50 of 0.24 mM, comparable to that of verinurad (IC50 1/4 0.17 mM). KPH2f also inhibited GLUT9 with an IC50 value of 9.37 +/- 7.10 mM, indicating the dual URAT1/GLUT9 targeting capability. In addition, KPH2f showed little effects on OAT1 and ABCG2, and thus was unlikely to cause OAT1/ABCG2-mediated drug-drug interactions and/or to neutralize the uricosuric effects of URAT1/GLUT9 inhibitors. Importantly, KPH2f (10 mg/kg) was equally effective in reducing serum uric acid levels and exhibited higher uricosuric effects in a mice hyperuricemia model, as compared to verinurad (10 mg/kg). Furthermore, KPH2f demonstrated favorable pharmacokinetic properties with an oral bioavailability of 30.13%, clearly better than that of verinurad (21.47%). Moreover, KPH2f presented benign safety profiles without causing hERG toxicity, cytotoxicity in vitro (lower than verinurad), and renal damage in vivo. Collectively, these results suggest that KPH2f represents a novel, safe and effective dual URAT1/GLUT9 inhibitor with improved druggabilities and is worthy of further investigation as an anti-hyperuricemic drug candidate.
学科与关键词
- CDER167, a dual inhibitor of URAT1 and GLUT9, is a novel and potent uricosuric candidate for the treatment of hyperuricemiaZhao, Ze An; Jiang, Yu; Chen, Yan-yu; Wu, Ting; Lan, Qun-sheng; Li, Yong-mei; Li, Lu; Yang, Yang; Lin, Cui-ting; Cao, Ying; Zhou, Ping-zheng; Guo, Jia-yin*; Tian, Yuan-xin*; Pang, Jian-xin*Acta Pharmacologica Sinica, 2022, 43(1): 121-132.被引 15
- Design, synthesis and activity evaluation of novel lesinurad analogues containing thienopyrimidinone or pyridine substructure as human urate transporter 1 inhibitorsZhang, Jian; Dong, Yue; Gao, Shenghua; Zhang, Xujie; Liao, Hui; Shi, Xiaoyu; Zhang, Zhijiao; Zhao, Tong; Liang, Ruipeng; Qi, Danhui; Wu, Ting*; Pang, Jianxin*; Liu, Xinyong*; Zhan, Peng*European Journal of Medicinal Chemistry, 2022, 244: 114816.被引 3
- Discovery of novel benzbromarone analogs with improved pharmacokinetics and benign toxicity profiles as antihyperuricemic agentsZhao, Zean; Liu, Jin; Yuan, Lin; Yang, Zichao; Kuang, Peihua; Liao, Hui; Luo, Jian; Feng, Huancun; Zheng, Fengxin; Chen, Yongjun; Wu, Ting; Guo, Jiayin; Cao, Ying; Yang, Yang; Lin, Cuiting; Zhang, Qun*; Chen, Jianjun*; Pang, Jianxin*European Journal of Medicinal Chemistry, 2022, 242: 114682.被引 3
